AML Hub cover art

AML Hub

AML Hub

By: Scientific Education Support
Listen for free

This Season's Biggest Deal | $0.99/mo for 3 months + $20 Audible bonus

Auto-renews at $8.99/mo. after 3 months - terms apply.
Summary
The AML Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education on acute myeloid leukemia (AML). Our aim is to enhance knowledge in AML through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.

Hosted on Acast. See acast.com/privacy for more information.

Scientific Education Support
Episodes
  • What does the future hold for next-generation menin inhibition in AML?
    Nov 18 2026

    The AML Hub was pleased to speak with Eunice Wang, Roswell Park Comprehensive Cancer Center, Buffalo, US. We asked, What does the future hold for next-generation menin inhibition in AML?


    During this interview, Wang discusses emerging strategies to optimize the efficacy of menin inhibitors for the treatment of acute myeloid leukemia (AML), including sequential treatment approaches to address acquired resistance, their integration into combination regimens for KMT2A-rearranged (KMT2Ar) or NPM1-mutated (NPM1m) AML, and their use alongside other targeted therapies for patients with co-occurring mutations.


    This educational resource is independently supported by Johnson & Johnson. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
    6 mins
  • The role of combination strategies in the treatment of FLT3-mutated acute myeloid leukemia
    Oct 20 2026

    During the latest AML Hub Steering Committee Meeting on August 11, 2026, key opinion leaders met to discuss the role of combination strategies in the treatment of FLT3-mutated (FLT3m) acute myeloid leukemia (AML). The meeting opened with a presentation by Gail J. Roboz, followed by a discussion featuring Agnieszka Wierzbowska, Charles Craddock, Jorge Sierra, Lars Bullinger, and Roland Walter.


    Roboz reviews the rationale for combination strategies in FLT3m AML and discusses updates presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting; May 29 – June 2, 2026, Chicago, US, and the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE. She considers potential future directions for FLT3 inhibitor-based combination strategies, followed by a discussion focused on how best to translate high remission rates into durable disease control and long-term outcomes. The steering committee also explores how treatment strategies may need to be individualized according to patient fitness, molecular profile, treatment response, and access to available therapies.


    Intended for healthcare professionals. This educational resource is independently supported by Daiichi Sankyo. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
    27 mins
  • Targeting menin: A paradigm shift in acute myeloid leukemia therapy
    Oct 13 2026

    Steering committee meeting


    In August, 2026, the AML Hub held a steering committee meeting where Joshua Zeidner presented on Targeting menin: A paradigm shift in acute myeloid leukemia therapy, followed by a panel discussion.


    This podcast is independently supported by Kura Oncology. Funders are allowed no influence.

    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
    34 mins
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.